DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis ...
A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as ...
UK MHRA grants marketing authorisation to Insmed Netherlands’ brensocatib to treat patients 12 years and older with non-cystic fibrosis bronchiectasis: United Kingdom Tuesday, F ...
Credit: Insmed. Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1. Treatment with brensocatib 10mg and 25mg significantly reduced the annual rate of pulmonary exacerbations in ...
BRESSO, Italy--(BUSINESS WIRE)--Zambon announced that colistimethate sodium powder for nebulizer solution, delivered by the I-neb AAD system obtained QIDP and “Fast Track” designation by the FDA for ...
The case suggests lung transplantation can be a feasible option for patients with lung involvement. A new case report is adding complexity to scientists’ understanding of a rare lysosomal storage ...
BRIDGEWATER, N.J., June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...
Treatment with the investigational anti-inflammatory drug brensocatib (formerly INS1007) significantly delayed the time to exacerbation in patients with the rare lung disease non-cystic fibrosis ...
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results